Alex Oshmyansky

In this enlightening conversation, Alex Oshmyansky, CEO and co-founder of Cost Plus Drugs, shares his journey from a young immigrant to a transformative force in the pharmaceutical industry. He discusses how the company is breaking down traditional drug pricing barriers with transparency and technology, revolutionizing access to medications. Oshmyansky also touches on his experiences transitioning from medicine to entrepreneurship, patience as a superpower, and the strategic partnerships that turned competitors into allies, all while advocating for affordable healthcare.

Sen. Chris Murphy, a U.S. Senator from Connecticut, discusses the political landscape around media consolidation and the role of state attorneys general in protecting democracy. Rep. Becca Balint shares insights on antitrust messaging and mobilizing coalitions for effective change. Workers' rights attorney David Seligman emphasizes the need for state enforcement to challenge corporate consolidation. Lastly, Cost Plus Drugs CEO Alex Oshmyansky sheds light on the fight for pharmaceutical transparency against entrenched industry players.

In this engaging conversation, Alex Oshmyansky, the CEO of Mark Cuban Cost Plus Drug Company and a practicing radiologist, discusses his mission to create a parallel supply chain to lower drug costs. He delves into the 'financial engineering' of the industry and the importance of transparency. Later, AJ Loiacono, CEO of CapitalRx, highlights the opaque nature of pharmacy benefit managers (PBMs) and their effect on pricing. Both guests passionately advocate for innovative solutions to revolutionize prescription drug accessibility and transparency.